Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus adjuvant endocrine therapy in early HR+ HER2- breast cancer
CTR20171172Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of abemaciclib in breast cancer, sponsored by Eli Lilly and Company. Started Feb 2018; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20171172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171172.